Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts

NCT04542824 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT04542824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04542824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts
Lead sponsor
Genmab
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 20, 2020
Completion date
September 30, 2027
Enrollment
78 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, marginal zone lymphoma, primary mediastinal large b cell lymphoma, small lymphocytic lymphoma